Humacyte, Inc. (NASDAQ:HUMA) is one of the penny stocks with potential to rise 1000 percent. On March 27, 2026, BTIG ...

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key ...

Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase ...

Humacyte is looking to sell 25 million shares in order to raise $20 million. ・The company said it plans to use the proceeds ...

This article first appeared on GuruFocus. Humacyte Inc (NASDAQ:HUMA) is set to release its Q4 2025 earnings on Mar 27, 2026.

Humacyte (NASDAQ:HUMA) outlined early commercial traction for Symvess and provided updates across its pipeline during its ...

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...

Humacyte, Inc. (HUMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt ...

(RTTNews) - Humacyte, Inc. (HUMA) has launched Symvess, a bioengineered vascular conduit for adults needing urgent revascularization due to extremity arterial injury when autologous vein grafts aren't ...